Dr. Badarinath is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2 Shircliff Way
Ste 800
Jacksonville, FL 32204Phone+1 904-388-2619Fax+1 904-388-0240
Education & Training
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 1996 - 2000- Emory University School of MedicineResidency, Internal Medicine, 1994 - 1997
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1994
Certifications & Licensure
FL State Medical License 2000 - 2025
GA State Medical License 1996 - 2001- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013
Clinical Trials
- Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Start of enrollment: 2011 Nov 01
- Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor Start of enrollment: 2012 Aug 07
- Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients Start of enrollment: 2014 Mar 08
Publications & Presentations
PubMed
- 8 citationsMulticenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.Craig L. Slingluff, Karl D. Lewis, Robert H.I. Andtbacka, John R. Hyngstrom, Mohammed M. Milhem
Journal for Immunotherapy of Cancer. 2021-10-01 - 12 citationsA phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.James R. Berenson, Robert F. Manges, Suprith Badarinath, Alan Cartmell, Kristi McIntyre
American Journal of Hematology. 2017-05-01 - 10 citationsPhase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.Lee S. Schwartzberg, Suprith Badarinath, Mark Keaton, Barrett H. Childs
Clinical Breast Cancer. 2014-06-01
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
